Arvinas

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. 

CEO
John G. Houston
CEOJohn G. Houston
Employees
445
Employees445
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2013
Founded2013
Employees
445
Employees445

ARVN Key Statistics

Market cap
2.24B
Market cap2.24B
Price-Earnings ratio
-5.05
Price-Earnings ratio-5.05
Dividend yield
Dividend yield
Average volume
724.28K
Average volume724.28K
High today
$33.97
High today$33.97
Low today
$32.65
Low today$32.65
Open price
$33.80
Open price$33.80
Volume
415.37K
Volume415.37K
52 Week high
$53.08
52 Week high$53.08
52 Week low
$13.57
52 Week low$13.57

ARVN News

Yahoo Finance 2d
Arvinas to Present at Upcoming Investor Conferences - Yahoo Finance

Arvinas Inc. NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of dr...

Arvinas to Present at Upcoming Investor Conferences - Yahoo Finance

Analyst ratings

90%

of 20 ratings
Buy
90%
Hold
10%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.